


REMARKS:**Status of Claims**

Claims 1-3, 5-9, 12-19, and 21 remain pending in the application.

Claims 4, 10-11, 20, and 22-24 were previously canceled.

Claim 19 has been amended by this response to insert the following compound:



Support for this amendment is found in the original specification at Example 3 (page 27). No new matter has been added.

Request for Allowance

Upon review of the file, Applicants learned that one of the compounds, specifically the compound of Example 3 (page 27), was inadvertently not included in Claim 19. Applicants are filing this RCE and amendment in order to correct this oversight. As the Examiner will readily appreciate, this compound falls within the elected group (see the Restriction Requirement mailed August 19, 2008). Also, since the subject matter of claim 1 was deemed allowable, Applicants respectfully submit that no (or at most a cursory) search should be needed to deem the species of Example 3 as allowable. Early and favorable indication of the same, entry of the foregoing amendment, and allowance of all of the pending claims is respectfully requested.

If the Examiner believes that a telephonic conversation with the undersigned would further prosecution, he is cordially invited to contact the undersigned.

Merck & Co., Inc.
2000 Galloping Hill Road
Patent Department, K-6-1, 1990
Kenilworth, NJ 07033
Tel: (908) 298-5734
Fax: (908) 298-5388

109803_1

Respectfully submitted,



Keith D. MacMillan
Attorney for Applicants
Reg. No. 47,212